Yanying Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanying Li has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- You Lu
Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
6 shared publications - Youling Gong
Division of Thoracic Tumor Multimodality Treatment and Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
6 shared publications - Bingwen Zou
Department of Radiation Oncology, Cancer Center & Institution of Stress Medicine, West China Hospital, Sichuan University, Chengdu, China
5 shared publications - Jiang Zhu
Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China
5 shared publications - Jianxin Xue
West China Hospital Sichuan University Chengdu China
5 shared publications - Meijuan Huang
Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
5 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- Open Access
- 1 October 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (10) , 2538-2548
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients
Background: The B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation is responsible for approximately 3% of acquired resistance mechanisms to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in advanced EGFR-mutant non-small cell lung cancer (NSCLC). This study investigated the efficacy and safety of a triple-targeted therapy combining EGFR/BRAF/mitogen-activated protein kinase kinase (MEK) inhibitors of dabrafenib, trametinib, and osimertinib in NSCLC patients with acquired BRAF V600E mutation after EGFR-TKI treatment. Methods: A multi-center retrospective review of medical records was performed to analyze EGFR-mutated advanced Chinese NSCLC patients who acquired the BRAF V600E mutation following EGFR-TKI treatment. All patients subsequently received dabrafenib, trametinib, and osimertinib. The clinical characteristics, progression-free survival (PFS), and adverse events (AEs) were documented. The in-vivo drug response of patient-derived organoids (PDOs) was observed. Next-generation sequencing (NGS) was performed upon progression to triple-targeted therapy. Results: Thirteen patients with BRAF V600E mutations were included. Following triple-targeted therapy, the corresponding objective response rate and disease control rate were 61.5% and 92.3%, respectively. The median PFS was 13.5 months (95% confidence interval: 6.6–20.4). PDOs derived from one patient’s tumor sample were established, revealing that the triple-targeted therapy had a significantly lower half-maximal inhibitory concentration (IC50) value compared to other regimens. The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib, and osimertinib; 99.25% for osimertinib plus vemurafenib; 98.92% for osimertinib, encorafenib, and cetuximab; and 62.83% for pemetrexed plus carboplatin. NGS analysis identified major resistance mechanisms following the triple-targeted therapy, including the EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and an off-target mechanism. Conclusions: EGFR/BRAF/MEK triple-targeted therapy is an effective and safe approach for treating EGFR-mutated NSCLC patients resistant to EGFR-TKIs with acquired BRAF V600E mutations.
- 1 October 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (10) , 2538-2548
Open AccessTriple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients
Background: The B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation is responsible for approximately 3% of acquired resistance mechanisms to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in advanced EGFR-mutant non-small cell lung cancer (NSCLC). This study investigated the efficacy and safety of a triple-targeted therapy combining EGFR/BRAF/mitogen-activated protein kinase kinase (MEK) inhibitors of dabrafenib, trametinib, and osimertinib in NSCLC patients with acquired BRAF V600E mutation after EGFR-TKI treatment. Methods: A multi-center retrospective review of medical records was performed to analyze EGFR-mutated advanced Chinese NSCLC patients who acquired the BRAF V600E mutation following EGFR-TKI treatment. All patients subsequently received dabrafenib, trametinib, and osimertinib. The clinical characteristics, progression-free survival (PFS), and adverse events (AEs) were documented. The in-vivo drug response of patient-derived organoids (PDOs) was observed. Next-generation sequencing (NGS) was performed upon progression to triple-targeted therapy. Results: Thirteen patients with BRAF V600E mutations were included. Following triple-targeted therapy, the corresponding objective response rate and disease control rate were 61.5% and 92.3%, respectively. The median PFS was 13.5 months (95% confidence interval: 6.6–20.4). PDOs derived from one patient’s tumor sample were established, revealing that the triple-targeted therapy had a significantly lower half-maximal inhibitory concentration (IC50) value compared to other regimens. The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib, and osimertinib; 99.25% for osimertinib plus vemurafenib; 98.92% for osimertinib, encorafenib, and cetuximab; and 62.83% for pemetrexed plus carboplatin. NGS analysis identified major resistance mechanisms following the triple-targeted therapy, including the EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and an off-target mechanism. Conclusions: EGFR/BRAF/MEK triple-targeted therapy is an effective and safe approach for treating EGFR-mutated NSCLC patients resistant to EGFR-TKIs with acquired BRAF V600E mutations.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 15 August 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (20) , 4098-4108
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
Purpose: Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the first time as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC). Patients and Methods: This prospective phase I study enrolled 29 patients and included a dose-escalation and dose-expansion phase. Patients received SBRT [30 Gray (Gy)/3f] to small lesions and LDRT (2 Gy/1f, 4 Gy/2f, or 10 Gy/5f) to a large lesion concurrently, followed by sintilimab (a programmed death-1 inhibitor). The primary endpoint was safety and tolerability; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: No dose-limiting toxicities were observed during the dose-escalation phase; 4 Gy/2f was the recommended LDRT dose. Median follow-up was 15.6 months. Treatment-related adverse events (TRAE) occurred in 96.6% (28/29) of patients [grade ≥ 3; 20.7% (6/29)]; 2 patients (6.9%) discontinued due to TRAEs. Seven patients experienced pneumonitis (grade 2, n = 6; grade 3, n = 1). Immune-related adverse events were noted in 58.6% (17/29) of patients. In patients with tumor assessment (n = 28), ORR and confirmed ORR were 60.7% and 57.1%, respectively. Median PFS was 8.6 months (95% confidence interval, 3.7–16.5), and median OS was not reached. Exploratory analyses suggested both expanded and newly emerging T-cell receptor clonotypes were associated with better PFS. Conclusions: The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with programmed death ligand-1–positive, driver gene–negative primary metastatic NSCLC.
- 15 August 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (20) , 4098-4108
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
Purpose: Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the first time as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC). Patients and Methods: This prospective phase I study enrolled 29 patients and included a dose-escalation and dose-expansion phase. Patients received SBRT [30 Gray (Gy)/3f] to small lesions and LDRT (2 Gy/1f, 4 Gy/2f, or 10 Gy/5f) to a large lesion concurrently, followed by sintilimab (a programmed death-1 inhibitor). The primary endpoint was safety and tolerability; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: No dose-limiting toxicities were observed during the dose-escalation phase; 4 Gy/2f was the recommended LDRT dose. Median follow-up was 15.6 months. Treatment-related adverse events (TRAE) occurred in 96.6% (28/29) of patients [grade ≥ 3; 20.7% (6/29)]; 2 patients (6.9%) discontinued due to TRAEs. Seven patients experienced pneumonitis (grade 2, n = 6; grade 3, n = 1). Immune-related adverse events were noted in 58.6% (17/29) of patients. In patients with tumor assessment (n = 28), ORR and confirmed ORR were 60.7% and 57.1%, respectively. Median PFS was 8.6 months (95% confidence interval, 3.7–16.5), and median OS was not reached. Exploratory analyses suggested both expanded and newly emerging T-cell receptor clonotypes were associated with better PFS. Conclusions: The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with programmed death ligand-1–positive, driver gene–negative primary metastatic NSCLC.
- Open Access
- 8 August 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (11) , 4511-4522
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
- 8 August 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (11) , 4511-4522
Open AccessIdentification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
- 19 May 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (20) , 2533-2543
Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting
Aims: To determine the antiemetic efficacy of a 6-day aprepitant schedule in patients receiving multiple-day cisplatin. Patients & methods: Patients diagnosed with lung cancer and who were chemothe... Plain language summary The aim of this study was to determine the effectiveness of a 6-day aprepitant schedule in patients receiving a multiple-day highly emetogenic chemotherapy drug (cisplatin). ...
- 19 May 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (20) , 2533-2543
Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting
Aims: To determine the antiemetic efficacy of a 6-day aprepitant schedule in patients receiving multiple-day cisplatin. Patients & methods: Patients diagnosed with lung cancer and who were chemothe... Plain language summary The aim of this study was to determine the effectiveness of a 6-day aprepitant schedule in patients receiving a multiple-day highly emetogenic chemotherapy drug (cisplatin). ...
- 1 February 2021
- Published by Elsevier in Lung Cancer
- Vol. 152, 104-108
Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients
- 1 February 2021
- Published by Elsevier in Lung Cancer
- Vol. 152, 104-108
Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 3050
A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.
3050Background: We performed the first phase I clinical trial (NCT02793856) to assess safety of CRISPR/Cas9-mediated knockout of PD-1 gene in autologous T lymphocytes (PD-1-/- T) therapy in patients with metastatic non-small cell lung cancer (NSCLC). Methods: We assigned patients with advanced NSCLC with positive PD-L1 expression who had progressed after 3rd line standard therapeutic regimens. Two patients were enrolled in Pre-A cohort who received PD-1-/- T therapy with 2 x 107 cells/kg for one cycle and were observed for another cycle. Then 3 cohorts (A, B, C) enrolled 3 patients in each group receiving PD-1-/- T cells therapy with 1×107/kg, 2×107/kg, 4×107/kg in each cycle, respectively. Patients received PD-1-/- T therapy until disease progression or study withdrawal. Primary outcome was safety. Secondary end points were 8 weeks disease control rate (DCR) and progression-free survival (PFS). In exploratory analyses, next-generation sequencing was performed on PD-1 editing region of T cells and CDR3 re...
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 3050
A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.
3050Background: We performed the first phase I clinical trial (NCT02793856) to assess safety of CRISPR/Cas9-mediated knockout of PD-1 gene in autologous T lymphocytes (PD-1-/- T) therapy in patients with metastatic non-small cell lung cancer (NSCLC). Methods: We assigned patients with advanced NSCLC with positive PD-L1 expression who had progressed after 3rd line standard therapeutic regimens. Two patients were enrolled in Pre-A cohort who received PD-1-/- T therapy with 2 x 107 cells/kg for one cycle and were observed for another cycle. Then 3 cohorts (A, B, C) enrolled 3 patients in each group receiving PD-1-/- T cells therapy with 1×107/kg, 2×107/kg, 4×107/kg in each cycle, respectively. Patients received PD-1-/- T therapy until disease progression or study withdrawal. Primary outcome was safety. Secondary end points were 8 weeks disease control rate (DCR) and progression-free survival (PFS). In exploratory analyses, next-generation sequencing was performed on PD-1 editing region of T cells and CDR3 re...
- Open Access
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 16 (7) , 746
Advances in imaging diagnosis of Budd-Chiari syndrome
布加综合征(Budd-Chiari syndrome, BCS)临床表现缺乏特异性, 易误诊. 随着多种影像诊断设备的进步和影像学检查方法的改进, 使得BCS的检出率提高. 超声、多层螺旋CT (multi-slice computed tomography, MSCT), 磁共振(MRI)等无创性影像学检查方法, 能够清晰显示肝静脉(hepatic vein, HV)、下腔静脉(inferior vena cave, IVC)狭窄部位和类型, 可指导临床治疗及效果的观察.
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 16 (7) , 746
Open AccessAdvances in imaging diagnosis of Budd-Chiari syndrome
布加综合征(Budd-Chiari syndrome, BCS)临床表现缺乏特异性, 易误诊. 随着多种影像诊断设备的进步和影像学检查方法的改进, 使得BCS的检出率提高. 超声、多层螺旋CT (multi-slice computed tomography, MSCT), 磁共振(MRI)等无创性影像学检查方法, 能够清晰显示肝静脉(hepatic vein, HV)、下腔静脉(inferior vena cave, IVC)狭窄部位和类型, 可指导临床治疗及效果的观察.